Certara, Arsenal Capital Partners agree to one-year lock-up on sale of shares

The company announced that Arsenal Capital Partners has agreed to a one-year lock-up on the sale of shares acquired by Arsenal and affiliates from EQT in a December 2022 transaction. “Arsenal has been an investor in Certara (CERT) since 2013. We are very proud of the contribution Certara has made to the development and acceptance of Model Informed Drug Discovery. Arsenal is committed to supporting Certara’s continued investment in the science and technologies necessary to enhance safe and effective pharmaceutical development for the benefit of patients around the world,” said Steve McLean, Senior Partner, Healthcare Group at Arsenal Capital Partners.